← Leaderboards
Finnian R McCausland
Brigham And Women'S Hospital
$3,327,661
Attributed
$3,845,461
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $722.6K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,845,461 · 6
By mechanism
R01$2,087,381 · 2
K23$964,183 · 1
U01$483,011 · 1
R03$179,000 · 1
K24$131,886 · 1
Top collaborators
- David M Charytan3 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Lynne W. Stevenson$4,462,830
- Richard M Mortensen$5,060,137
- Amil M Shah$21,763,052
- Katherine Scovner Ravi$1,177,756
- Mehdi Najafzadeh$3,558,051
Others in their field
Top investigators on “United States”
- Leonard Freedman · Leidos Biomedical Research, Inc.$818,172,357
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$638,373,375
- David Heimbrook · Leidos Biomedical Research, Inc.$632,657,800
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United StatesBlood PressureMaintenanceInnovationHemodialysisClinically RelevantReportingHigh RiskCardiovascular SystemMortalityPatient CarePerformanceCardiovascular DiseasesCessation Of LifeEventMorbidity - Disease RateRandomizedHypotensionHemodynamicsFrequenciesMulticenter StudiesKidney FailureFluid OverloadAdverse Effects
Grant awards (15)
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)$342,085
R01 · FY2025 · DK
Volume And Patient-Oriented Research in Chronic Kidney Disease (VAPOR-CKD)$131,886
K24 · FY2025 · HL · contact PI
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation$343,680
R01 · FY2024 · DK · contact PI
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)$328,965
R01 · FY2024 · DK
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)$364,551
R01 · FY2023 · DK
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation$358,000
R01 · FY2023 · DK · contact PI
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation$350,100
R01 · FY2022 · DK · contact PI
Patient Symptoms on Hemodialysis-Timing, Variability and Causes$89,500
R03 · FY2020 · DK · contact PI
Cardiac Complications of Hemodynamic Instability during Hemodialysis$197,640
K23 · FY2019 · DK · contact PI
Patient Symptoms on Hemodialysis-Timing, Variability and Causes$89,500
R03 · FY2019 · DK · contact PI
Cardiac Complications of Hemodynamic Instability during Hemodialysis$197,640
K23 · FY2018 · DK · contact PI
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD$483,011
U01 · FY2017 · DK · contact PI
Cardiac Complications of Hemodynamic Instability during Hemodialysis$197,640
K23 · FY2017 · DK · contact PI
Cardiac Complications of Hemodynamic Instability during Hemodialysis$185,015
K23 · FY2016 · DK · contact PI
Cardiac Complications of Hemodynamic Instability during Hemodialysis$186,248
K23 · FY2015 · DK · contact PI